Roche Holdings AG Basel ADR (RHHBY) Shares Sold by Oak Associates Ltd. OH
Oak Associates Ltd. OH trimmed its holdings in Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) by 0.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 193,735 shares of the company’s stock after selling 390 shares during the period. Oak Associates Ltd. OH’s holdings in Roche Holdings AG Basel were worth $6,663,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the business. Beck Mack & Oliver LLC acquired a new position in shares of Roche Holdings AG Basel in the 1st quarter valued at about $203,000. South Texas Money Management Ltd. acquired a new position in shares of Roche Holdings AG Basel in the 1st quarter valued at about $215,000. MAI Capital Management acquired a new position in shares of Roche Holdings AG Basel in the 1st quarter valued at about $220,000. Private Capital Group LLC lifted its stake in shares of Roche Holdings AG Basel by 86.3% in the 4th quarter. Private Capital Group LLC now owns 6,893 shares of the company’s stock valued at $213,000 after purchasing an additional 3,193 shares in the last quarter. Finally, Dearborn Partners LLC lifted its stake in shares of Roche Holdings AG Basel by 8.7% in the 4th quarter. Dearborn Partners LLC now owns 8,347 shares of the company’s stock valued at $259,000 after purchasing an additional 667 shares in the last quarter. 0.31% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have recently weighed in on RHHBY shares. Argus started coverage on Roche Holdings AG Basel in a research note on Monday, January 28th. They issued a “buy” rating on the stock. Credit Suisse Group raised Roche Holdings AG Basel from an “underperform” rating to a “neutral” rating in a research note on Monday, January 28th. Six equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $34.50.
ILLEGAL ACTIVITY NOTICE: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.thecerbatgem.com/2019/05/26/roche-holdings-ag-basel-adr-rhhby-shares-sold-by-oak-associates-ltd-oh.html.
Roche Holdings AG Basel Company Profile
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Featured Article: What is the Difference Between Common Shares and Convertible Shares?
Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holdings AG Basel ADR (OTCMKTS:RHHBY).
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.